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Background: Organ donor shortage remains as one of the limiting factors for lung trans-
plantation. Given the increase in waiting time, preoperative condition has worsened and 
affects surgical outcomes. This study aimed to evaluate the immediate postoperative 
and long-term outcomes of lung transplantation in extended-criteria donor (ECD) lungs 
compared with standard-criteria donor (SCD) lungs.
Methods: A total of 246 patients who had undergone double-lung transplantation during 
the study period were enrolled. SCD was defined based on the following characteris-
tics: age <55 years, <20 pack-years smoking history, and PaO2/fraction of O2 ratio >300 
mmHg. Organ donors who do not fulfill these criteria were classified as ECD. Pre- and 
postoperative data for outcomes and survival data were analyzed. 
Results: ECD showed significant association with extracorporeal membrane oxygen-
ation weaning in the operating room (hazard ratio [HR], 0.531; 95% confidence interval 
[CI], 0.291–0.970; P=0.039) considering recipient’s age and status at operation. The ECD 
group showed comparable survival rate with the SCD group (HR, 1.413; 95% CI, 0.885–
2.255; P=0.148), with adjustment of other factors. However, when the recipient had Kore-
an Network for Organ Sharing (KONOS) status 0 at the time of transplantation (HR, 1.662; 
95% CI, 1.025–2.568; P=0.039), G3 primary graft dysfunction at 72 hours after surgery 
(HR, 2.508; 95% CI, 1.416–4.440; P=0.002) was a risk factor that decreased survival.
Conclusions: The outcome of ECD is not inferior to that of SCD. Therefore, ECD lung 
should be considered a potential donor organ following active donor management rather 
than a contraindication of transplantation in highly selected recipients.
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INTRODUCTION
Lung transplantation is the only treatment option for pa-
tients with end-stage lung disease. Organ donor shortage 
remains as one of the limiting factors for the widespread 
usage of lung transplantation. This shortage of organ 
donors is due to the low rate of organ donations from 
brain dead donors (BDDs) and the low procurement rate 
of lungs. In Korea, organ donation from BDDs was low at 
1.78 per million population (20.5%, 92/449); in truth, only 
92 of the 255 patients who waited for lung transplantation 
had undergone lung transplantation in 2018 [1]. Given the 
increase in the waiting time caused by the shortage of 
donated organs, the numbers of waiting-list patients who 
required hospital admission and who required extracor-
poreal membrane oxygenation (ECMO) and mechanical 
ventilation before transplantation are increasing [2]. In 
2018, the proportion of lung transplant patients who re-
ceived ECMO or mechanical ventilator support at the time 
of transplantation was 55.4%, which was more than half of 
all transplantations performed in South Korea [1]. The pre-
operative condition of the waiting patient also affects the 
outcomes of surgery.
A large number of BDDs had not fulfilled the standard 
criteria for lung donation. Thus, many transplant programs 
had started to discuss and considered extended-criteria 
donors (ECD). Marginal donor or ECD is defined as an or-
gan donor who does not completely satisfy the standard 
lung donor criteria, and the criteria differ slightly depend-
ing on published results or institution, but the ECDs are 
generally older, have more smoking history, and have lower 
PaO2/fraction of O2 (P/F) ratio than the ideal donor. ECDs 
showed no significant difference on the short-term out-
come and long-term survival in most previous studies, but 
in some studies, smoking history of more than 20 pack-
years (PYR) showed decreases in the survival rate [3], and 
a P/F ratio of 300 mmHg or less increased the risk of G3 
PGD at postoperative 48 hours [4]. Besides, since the char-
acteristics of the recipients have a significant effect on the 
course of transplantation [5-7], it is also important to un-
derstand how these marginal donors affect the outcomes 
of high-risk recipients.
Our institution has been actively using ECD organs, and 
since 2014, more than 25% of all lung transplants used 
ECD lungs every year. Thus, this study aimed to evaluate 
the immediate postoperative and long-term outcomes of 
lung transplantation in ECD lungs compared with stan-
dard-criteria donor (SCD) lungs. In addition, this study will 
discuss the safety of ECD lungs and appropriate indica-
tions of recipients using ECD lungs and investigate ways 
to increase the pool of organ donation, distribute it to ap-
propriate recipients, and help in the proper distribution of 
limited donor organs.
METHODS
The retrospective study of patients’ electronic data and 
the study protocol were approved by the Institutional Re-
view Board of Severance Hospital (IRB No. 4-2020-0363). 
Informed consent was waived. This study was conducted 
in compliance with the principles of the Declaration of Hel-
sinki.
Description of Participants
A total of 267 patients who had undergone double-lung 
transplantation from January 1, 2010, to May 31, 2019, 
were identified. Of these patients, 21 who received com-
bined-organ transplantation, single-lung transplantation, 
and re-transplantation were excluded. Finally, 246 patients 
were enrolled in this study. Pre- and postoperative data for 
outcomes and survival data were analyzed. The SCD group 
included recipients with the following donor lung charac-
teristics: age <55 years, <20 PYR smoking history, and P/F 
ratio >300 mmHg. Recipients who received donor organs 
that do not fulfill these criteria were classified to the ECD 
group. 
Data Collection
Data for analyses included recipient’s age, sex, smoking 
status, pre-existing diseases, and preoperative mechanical 
support and donor’s age, sex, smoking status, duration of 
mechanical ventilation, and organ size mismatch. A Ko-
HIGHLIGHTS
• Extended­criteria donor (ECD) lungs are not inferior to 
standard­criteria donor lungs. 
• Recipient characteristics such as preoperative Korean 
Network for Organ Sharing (KONOS) status 0 have a 
more important effect on patient’s outcome. 
• ECD lungs did not affect G3 primary graft dysfunction 
at 72 hours after transplant.
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rean Network for Organ Sharing (KONOS) status 0 means 
that the recipients received ventilator support or ECMO 
support at the time of transplantation. Operative data in-
cluding ischemic time and operation time were collected. 
Postoperative outcome data included weaning of ECMO in 
the operating room (OR), length of mechanical ventilation, 
and PGD 72 hours after surgery. 
Surgical Technique and Postoperative Management
The surgical technique and postoperative management 
were the same as described in a previous study [8]. The 
surgical technique for transplantation was performed via 
a clamshell incision. In our hospital, since March 2013, 
peripheral veno-arterial ECMO via the right femoral vein 
and the right femoral artery was performed in all patients 
for cardiopulmonary support. The ECMO apparatus was 
inserted after gaining access to the intrathoracic space. 
Upon completion of anastomosis, reperfusion of the donor 
lung was performed with a delivered fraction of inspired 
oxygen (FiO2) value of 0.2, with mechanical ventilation. 
Patients with P/F ratio >200 mmHg, ECMO, and stable he-
modynamic status were weaned from ECMO in the OR af-
ter the transplantation procedure. If the P/F ratio was less 
than 200 mmHg, the catheter was inserted into the right 
internal jugular vein, and the ECMO mode was changed to 
the veno-venous mode. After the graft function was stabi-
lized, the patients were weaned from ECMO in the inten-
sive care unit.
We performed routine fiberoptic bronchoscopy on the 
first day after surgery to implement pulmonary toileting 
and to evaluate bronchial anastomosis. Bacterial culture 
and Aspergillus antibody test of the bronchoalveolar 
lavage fluid obtained during bronchoscopy and weekly 
sputum cultures were also performed in these patients. 
All patients received triple immunosuppressive therapy 
consisting of mycophenolate mofetil, prednisone, and tac-
rolimus. Prophylactic regimens for Pneumocystis carinii 
(trimethoprim-sulfamethoxazole), fungi (itraconazole), and 
cytomegalovirus (valganciclovir) were initiated. Antibiotic 
therapy with fourth-generation cephalosporins (cefepime) 
and teicoplanin was initiated, with the dosing regimen 
adjusted on the basis of the results from the antibiotic 
sensitivity of cultures established from the perioperative 
samples. Based on our protocol, antibiotics were typically 
used for 2 weeks, unless the bacterial cultures tested pos-
itive, in which case antibiotics were used until the bacterial 
cultures tested negative. 
Statistical Analysis
Statistical analyses were performed using IBM SPSS ver. 
23 (IBM Corp., Armonk, NY, USA). Clinical parameters were 
described as mean±standard deviation for continuous vari-
ables, and some non-metric independent variables were 
described as median (interquartile range). Categorical vari-
ables were described as frequencies (%) for categorical 
variables. Student t-test was used to compare continuous 
variables for parametric test and Mann-Whitney U-test for 
non-parametric test, and the chi-square test was used to 
compare categorical variables. Survival was calculated 
by the Kaplan-Meier method and compared with log-rank 
test. Cox proportional hazard model was used to identify 
risk factors with recipient age, recipient status at the time 
of transplantation, weaning from ECMO in the OR, G3 PGD 
at 72 Hours after transplantation, and donor group as co-
variates. Risk factors were significantly associated with 
survival at P<0.05.
Table 1. Baseline characteristics of the donors and recipients
Variable SCD (n=179) ECD (n=67) P-value
Recipient age (yr) 50.46±13.35 55.27±10.47 0.004
Age >65 years 16 (8.9) 9 (13.4) 0.344
Male sex 108 (60.3) 40 (59.7) 0.928
Status 0 60 (33.5) 29 (32.6) 0.156
Disease entity 0.108
   IPF 96 (53.6) 37 (55.2)
   CTD-ILD 21 (11.7) 13 (19.4)
   Bronchiectasis 17 (9.5) 4 (6.0)
   PAH 8 (4.5) 0
   BOS after BMT 16 (8.9) 3 (4.5)
   Emphysema 1 (0.6) 3 (4.5)
   LAM 7 (3.9) 2 (3.0)
   Others 13 (7.3) 5 (7.5)
Donor age (yr) 39.43±10.89 51.03±10.38 <0.001
Donor smoking Hx (PYR) 8.02±5.73 27.99±17.09 <0.001
PF ratio 470.72±80.25 409.58±115.77 <0.001
Values are presented as mean±standard deviation or number (%).
SCD, standard-criteria donor; ECD, extended-criteria donor; IPF, idiopathic 
pulmonary fibrosis; CTD-ILD, connective tissue disease-associated 
interstitial lung disease; PAH, pulmonary arterial hypertension; BOS, 
bronchiolitis obliterans syndrome; BMT, bone marrow transplantation; 
LAM, lymphangioleiomyomatosis; Hx, history; PYR, pack-years; P/F, PaO2/
fraction of O2. 
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RESULTS
The ECD and SCD groups were composed of 67 (27.2%) 
and 179 (72.8%) patients, respectively. In the ECD group, 
31 donors (46.3%) were ≥55 years old, 26 donors (38.8%) 
had a smoking history >20 PYR, and 17 donors (25.4%) had 
P/F ratio <300 mmHg. Donor and recipient characteristics 
in each group are described in Table 1 and postoperative 
outcomes are shown in Table 2. The recipients were sig-
nificantly younger (50.46±13.35 vs. 55.27±10.47, P=0.004) 
and the rate of ECMO weaning in the OR was significantly 
higher (61.2% vs. 45.2%, P=0.047) in the SCD group than in 
the ECD group. Other preoperative characteristics and op-
erative outcomes were not significantly different between 
the two groups.
In the logistic regression model, ECD was significantly 
associated with risk for failure of ECMO weaning in the 
OR (hazard ratio [HR], 0.522; 95% confidence interval [CI], 
0.286–0.951; P=0.034), but ECD was not associated with 
risk of G3 PGD at 72 hours after transplantation in the uni-
variate analysis (HR, 1.734; 95% CI, 0.875–3.436; P=0.114). 
In the multivariate analysis, ECD also showed significant 
association with risk for failure of ECMO weaning in the OR 
(HR, 0.531; 95% CI, 0.291–0.970; P=0.039) but no associ-
ation with risk of G3 PGD at 72 hours after transplantation 
(HR, 1.652; 95% CI, 0.827–3.302; P=0.155) considering 
recipient’s age and status at operation (Table 3).
Overall survival rate of ECD was not significantly differ-
ent (3-year survival rate, 60.4% vs. 43.8%; P=0.120) (Fig. 1) 
from that of SCD. The ECD group showed comparable sur-
vival rate with the SCD group (HR, 1.413; 95% CI, 0.885–
2.255; P=0.148) (Table 4), with adjustment for recipient 
age, recipient status at transplantation, ECMO weaning in 
the OR, and G3 PGD 72 hours after transplantation. How-
ever, when the recipient had KONOS status 0 at the time of 
transplantation (HR, 1.622; 95% CI, 1.025–2.568; P=0.039), 
G3 PGD at 72 hours after surgery (HR, 2.508; 95% CI, 
1.416–4.440; P=0.002) was a risk factor that decreased 
survival (Table 4).
A subgroup analysis was performed to confirm the 
effect of ECD according to recipient factor which affected 
survival rate in the hazard model. The survival of the ECD 
and SCD groups was compared by dividing the age of the 
recipients into >65 years and ≤65 years. The ECD group 
tended to have lower survival rate than the SCD group, 
Table 2. Postoperative outcomes 
Variable SCD (n=179) ECD (n=67) P-value
Ischemic time (min) 329.00±79.42 326.79±78.53 0.846
ECMO weaning at OR 90 (61.2) (n=147) 28 (45.2) (n=62) 0.047
PGD G3 after 72 hours 31 (18.6) 17 (28.3) 0.140
Hemodialysis 37 (20.7) 15 (22.4) 0.861
Tracheostomy 40 (22.3) 18 (26.9) 0.501
Length of mechanical  
ventilation (day)
4±8 3±7 0.349
Length of hospital  
stay (day)
32.0±31 30.0±33 0.385
Operative mortality 38 (21.2) 14 (20.9) 0.955
Postoperative 1-year FVC 
(% predicted)
73±24.5 78.0±45.5 0.624
Postoperative 1-year FEV1 
(% predicted)
66.5±21.75 67.0±35 0.626
Values are presented as mean±standard deviation or number (%).
SCD, standard-criteria donor; ECD, extended-criteria donor; ECMO, 
extracorporeal membrane oxygenation; OR, operating room; PGD, primary 
graft dysfunction; FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 second.
Table 3. Risk analysis for ECMO weaning at the OR and PGD G3 72 hours after operation 
Variable
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
ECMO weaning at OR
   R_age >65 years 0.900 0.383–2.115 0.810 0.913 0.384–2.171 0.837
   R_status 0 0.748 0.425–1.318 0.316 0.774 0.437–1.374 0.382
   ECD 0.522 0.286–0.951 0.034 0.531 0.291–0.970 0.039
PGD G3 after 72 hours
   R_age >65 years 1.021 0.361–2.892 0.968 1.092 0.379–3.147 0.870
   R_status 0 1.859 0.970–3.559 0.062 1.789 0.929–3.444 0.082
   ECD 1.734 0.875–3.436 0.114 1.652 0.827–3.302 0.155
ECMO, extracorporeal membrane oxygenation; OR, operating room; PGD, primary graft dysfunction; HR, hazard ratio; CI, confidence interval; R_age, 
recipient age; R_status 0, recipient Korean Network for Organ Sharing status 0 at the time of operation; ECD, extended-criteria donor.
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but no significant difference in survival rate was found 
between the ECD and SCD groups when the recipient was 
≤65 years old (Fig. 2). Second, the survival rates of the 
ECD and SCD groups were compared by dividing patients 
whether they have KONOS status 0 or not at the time of 
transplantation. No significant difference was found in the 
survival rate between the ECD and SCD groups according 
to recipient status, but when the recipient had KONOS 
status 0, both ECD and SCD groups had significantly lower 
survival rate than patients who had no KONOS status 0 
from SCD (Fig. 3).
DISCUSSION
This study was conducted to determine the feasibility of 




















































Fig. 1. Overall survival. SCD, standard-criteria donor; ECD, extended-crite-
ria donor. 
Table 4. Risk analysis for overall survival
Variable
Multivariate
HR 95% CI P-value
R_age >65 yr 1.565 0.848–2.887 0.152
R_status 0 1.622 1.025–2.568 0.039
ECD 1.413 0.885–2.255 0.148
ECMO weaning at OR 0.952 0.552–1.644 0.861
PGD G3 after 72 hours 2.508 1.416–4.440 0.002
HR, hazard ratio; CI, confidence interval; R_age, recipient age; R_status 
0, recipient Korean Network for Organ Sharing status 0 at the time of 
operation; ECD, extended-criteria donor; ECMO, extracorporeal membrane 













































































Fig. 2. Survival rate according to recipi-
ents aged >65 years and donor group. R_
age, recipient age. a)P-value between the 
standard-criteria donor (SCD) group and 
extended-criteria donor (ECD) group among 
recipients aged >65 years; b)P-value between 
recipients aged >65 years and >65 years in 
the ECD group. 
 https://doi.org/10.4285/kjt.2020.34.3.185190
Korean J Transplant · September  2020 · Volume 34 · Issue 3
found no significant differences in early postoperative 
outcomes including length of mechanical ventilation and 
length of hospital stay between the ECD and SCD groups. 
In the risk analysis, ECD lungs affected ECMO weaning in 
the OR but not G3 PGD at 72 hours after transplantation. 
As regards overall survival, no significant difference was 
found between the two groups, but it was significantly low 
in recipients with KONOS status 0 at transplantation; more-
over, it tended to be worse in the ECD group.
After the emergence of the ECD concept, the proportion 
of ECD in transplanted lungs has increased. The defini-
tion of ECD differs slightly depending on the institution or 
study, but most are based on age, smoking history, and P/
F ratio. According to Yeo et al. [9], more than 60% of BDD 
lungs used in Korea from 2012 to 2016 were categorized 
as ECD. In our study, the proportion of recipients who had 
received ECD lungs was 26.6%, and when divided by year, 
the use of ECD lungs increased from 2012 and gradually 
increased since then, showing a rate approximately 30% in 
recent years (Supplementary Table 1). Lungs from BDDs 
have a lower procurement rate than other organs. In Korea, 
the lung utility rate of BDDs was 20.5% in 2018, which was 
higher than the previous rate of less than 20%, but is still 
less than half compared with that of other thoracic organs, 
such as the heart. According to Yeo et al. [9], 74% of all 
BDDs in Korea were not evaluated for lung transplantation, 
82 (8%) of which were SCD and 337 (33%) were ECD. 
There were several previous studies of older donors. 
According to some studies, organs from donors aged 55–
64 years did not affect short-term and long-term outcomes 
[10,11]; however, donors aged >65years showed slightly 
decreased long-term outcome [11]. On the contrary, Schul-
tz et al. showed lower chronic lung allograft dysfunction 
(CLAD)-free survival in donors aged ≥55 years [12]. More-
over, Hayes et al. [13] used United Network for Organ Shar-
ing (UNOS) data and showed that organs from older do-
nors did not affect outcomes of recipients aged ≥50 years, 
but younger recipients showed limited outcomes. Some 
studies reported about the effect of donor smoking history 
on posttransplant outcomes. Based on UNOS data, Reyes 
et al. [3] had shown that organs from donors with smok-
ing history >20 PYR appeared to have slightly worse long-
term survival with a not powerful effect. Schultz et al. [12] 
reported that current or former smokers have decreased 
overall survival but have no influence on CLAD-free sur-
vival after transplantation. In terms of PaO2, Zych et al. [4] 
had shown that the rate of G3 PGD at 48 hours after trans-
plantation was significantly higher in donors with P/F ratio 
<300 mmHg, and other early and late outcomes had no 
difference [4]. In addition, Reyes et al. [3] had shown that 
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Fig. 3. Survival rate according to recipients 
with Korean Network for Organ Sharing 
(KONOS) status 0 at transplantation and 
donor group. a)P-value between the stan-
dard-criteria donor (SCD) group and extend-
ed-criteria donor (ECD) group of recipients 
with status 0 at transplantation; b)P-value 
between recipients with status 0 at trans-
plantation and no status 0 at transplantation 
in the ECD group. 
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In our study, the characteristics of recipients rather 
than the characteristics of donors had influenced the 
posttransplantation outcome. G3 PGD at 72 hours after 
transplantation and preoperative recipient of status 0 were 
found to be significant risk factors to decreased survival. 
Other previous studies presented that recipients’ char-
acteristics determined the outcomes of transplantation. 
Pretransplantation mechanical ventilation has been asso-
ciated with posttransplantation mortality [6]. The Toronto 
group reported that the 30-day mortality rate was higher in 
“non-guideline” recipients than in “guideline” recipients of 
ECD lungs [14]. Sommer et al. [5] also studied outcomes 
of ECD lungs according to the allocation of recipients, and 
they showed that marginal-donor lungs for stable recipi-
ents were acceptable. In a previous study based on UNOS 
data, patients who received ECD lungs had low survival 
rate; especially, those with lung allocation score ≥70 who 
received ECD have the lowest survival rate [15].
This study has some limitations. First, given the single 
institutional setting and retrospective design, the results of 
this study cannot represent all outcomes of ECD. Second, 
because factors constituting the ECD are not considered 
separately, identifying the detailed risk for each factor is 
difficult. Third, patients’ long-term outcomes were com-
pared only with simple survival, and the outcomes of ECD 
such as quality of life were not qualitatively compared.
In conclusion, the outcome of ECD is not inferior to that 
of SCD. However, recipient characteristics such as age and 
KONOS status at the time of operation are thought to have 
a more important effect on patient’s outcome. Therefore, 
ECD lung should be considered a potential donor organ 
following active donor management rather than a contrain-
dication of transplantation in highly selected recipients.
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